A Multi-center, Phase II, Single-arm Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
Latest Information Update: 07 Mar 2024
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 21 Mar 2022 New trial record